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Background: The PLATelet inhibition and patient Outcomes trial (PLATO) showed that, in patients with acute coronary syndromes (ACS), treatment 
with ticagrelor as compared with clopidogrel significantly reduces the risk of death from vascular causes, myocardial infarction (MI) or stroke without 
an increase in the rate of overall major bleeding. The present study used the Register of Information and Knowledge about Swedish Heart Intensive 
care Admission (RIKS-HIA) to assess whether the patient population enrolled in PLATO was representative of the unselected ACS population captured 
by this national heart registry.
Methods: RIKS-HIA registers all patients admitted to Swedish coronary care units, regardless of diagnosis. It includes data on over 500,000 
hospital admissions, and records information on demographics, medication use, interventions and outcomes. The database was retrospectively 
analysed to identify all individuals admitted with an index diagnosis of ACS from 1998 to 2005. A second analysis was performed of all patients with 
an index diagnosis of ACS during 2007. The PLATO inclusion and exclusion criteria were applied to the total ACS population in RIKS-HIA to assess 
what proportion of patients would have been eligible for inclusion in the trial.
Results: In 1998-2005, a total of 205,269 patients aged ≥ 18 years had an index diagnosis of ACS recorded in RIKS-HIA. Of these, 41% had non-
ST-elevation MI, 29% had unstable angina, 24% had ST-elevation MI and 6% had left bundle branch block acute MI. Almost two-thirds of the total 
study cohort met the PLATO inclusion criteria (n = 132,018; 64.3%); the mean age of those who met these criteria was 72.3 years and 36.9% were 
female. In 2007, 24,695 patients had an index diagnosis of ACS recorded in RIKS-HIA, 79.4% of whom met the PLATO inclusion criteria.
Conclusion: The PLATO inclusion criteria would have captured the majority of patients in the Swedish general population with a diagnosis of ACS in 
1998-2005 (64%) and 2007 (79%). This suggests that the PLATO study population is approximately representative of an unselected ACS population 
seen in a national heart registry.
